Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
Perez, Edith A. , Barrios, Carlos H. , Eiermann, W., Im, Young‐Hyuck , Conte, PierFranco , Pieńkowski, Tadeusz , Burris, Howard A. , Petersen, Jennifer, Haas, Sanne de , Hoersch, Silke, Patre, Monika, Ellis, Paul Anthony, Conte, Pierfranco , Toi, Masakazu , Martín, Miguel , Pivot, Xavier B. , Petersen, Jennifer A.

Mayo Clinic

Cancer | July 18, 2019 | Volume: 125 | Issue: 22 | Pages: 3974-3984

10.1002/cncr.32392 | PMID 31318460 Get It

Background In the phase 3 MARIANNE trial, trastuzumab emtansine (T‐DM1) with or without pertuzumab showed noninferior progression‐free survival and better tolerability than trastuzumab plus a taxane (HT) for the first‐line treatment of human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer. This article reports the final descriptive overall survival (OS) analysis, updated safety data, and additional patient‐reported outcomes and biomarker analyses. Methods OS was assessed in 1095 patients with HER2‐positive breast cancer and no prior therapy for advanced disease who had been randomized to HT, T‐DM1 plus a placebo (hereafter T‐DM1), or T‐DM1 plus pertuzumab (T‐DM1+pertuzumab). A post hoc exploratory landmark analysis of OS, baseline patient and disease characteristics, and tumor biomarkers in patients with and without an objective tumor response (OR) according to the Response Evaluation Criteria in Solid Tumors within 6.5 months of randomization was conducted. Results The median OS was similar across groups (50.9, 53.7, and 51.8 months for the HT, T‐DM1, and T‐DM1+pertuzumab groups, respectively). Among patients with an OR, the median OS was longer with T‐DM1 (64.4 months) and T‐DM1+pertuzumab (not reached) versus HT (56.3 months). No baseline characteristics or biomarkers were strongly associated with OR. The incidence of grade 3 or higher adverse events was greater with HT (55.8%) than T‐DM1 (47.1%) or T‐DM1+pertuzumab (48.6%). The median time to clinically meaningful deterioration (a 3‐point or greater change) in neurotoxicity symptoms was shorter with HT (2.1 months) and T‐DM1+pertuzumab (4.2 months) than T‐DM1 (6.2 months). Fewer patients reported alopecia and diarrhea and were bothered by treatment side effects in the T‐DM1 arm. Conclusions These results support T‐DM1 as a first‐line treatment for patients with HER2‐positive metastatic breast cancer who are deemed unsuitable for taxane‐based therapy.
Pain and opioid prescriptions vary by procedure after breast surgery
Murphy, Brittany L. , Thiels, Cornelius A. , Hanson, Kristine T. , McLaughlin, Sarah A. , Jakub, James W. , Gray, Richard J. , Ubl, Daniel S. , Habermann, Elizabeth B. , Jakub, James W , Habermann, Elizabeth , Thiels, Cornelius A , Hanson, Kristine

Mayo Clinic

Journal of Surgical Oncology | July 12, 2019 | Volume: 120 | Issue: 4 | Pages: 593-602

10.1002/jso.25636 | PMID 31297826 Get It

AbstractBackgroundWith the opioid epidemic in the United States, evaluating opioid prescribing patterns is essential. We evaluated opioids prescribed at discharge following breast surgery and their association with patient factors and pain scores.MethodsWe retrospectively identified adult patients who underwent a mastectomy for cancer at Mayo Clinic sites from January 2010 to December 2016. Pain scores and prescription data were compared across operations and patient factors by univariate and multivariable analyses.ResultsOf 4021 patients, 3782 (94.1%) received an opioid prescription. Median oral milligram morphine equivalents (MME) were similar across all site‐specific procedure groups (medians ranging from 225 to 375) while pain scores ranged from 1 to 4. Patients undergoing bilateral mastectomy (BM) and immediate breast reconstruction (IBR) reported the greatest pain scores. Pain scores did not vary with age or diagnosis for patients undergoing unilateral mastectomy or BM with lymph node surgery and IBR procedures.On multivariable analysis, variables associated with a MME discharge prescription >Q4 values included age, body mass index, site, year, inpatient status, and pain before discharge >3.ConclusionPatient‐reported pain following breast surgery varied by procedure, while MMEs prescribed remained similar. This suggests current opioid prescribing does not reflect intensity of pain and requires further research to optimize discharge opioid prescribing practices.
Palliative Inotrope Therapy
Chuzi, Sarah , Allen, Larry A. , Warraich, Haider J. , Dunlay, Shannon M.

Mayo Clinic

JAMA Cardiology | July 3, 2019 | Volume: 4 | Issue: 8 | Pages: 815

10.1001/jamacardio.2019.2081 | PMID 31268467 Get It

Enablers and Barriers to Implementing ICU Follow-Up Clinics and Peer Support Groups Following Critical Illness: The Thrive Collaboratives*
McPeake, Joanne , Hibbert, Elizabeth , Boehm, Leanne M. , Aparanji, Krishna, Bakhru, Rita N. , Bastin, Anthony J. , Beesley, Sarah J. , Beveridge, Lynne , Butcher, Brad W. , Drumright, Kelly, Eaton, Tammy L. , Firshman, Penelope , Fritschle, Andrew, Hope, Aluko A. , Johnson, Annie, Kenes, Michael T. , Khan, Babar , Kloos, Janet A. , Kross, Erin K. , MacTavish, Pamela , Meyer, Joel , Montgomery-Yates, Ashley , Quasim, Tara , Saft, Howard L., Slack, Andrew, Stollings, Joanna L. , Weinhouse, Gerald L., Whitten, Jessica, Netzer, Giora, Hopkins, Ramona O., Iwashyna, Theodore J. , Sevin, Carla M. , Haines, Kimberley , Farley, Thomas, Holdsworth, Clare, Mikkelsen, Mark E.

Mayo Clinic

Critical Care Medicine | June 28, 2019 | Volume: 47 | Issue: 9 | Pages: 1194-1200

10.1097/ccm.0000000000003818 | PMID 31241499 Get It

Objectives: Data are lacking regarding implementation of novel strategies such as follow-up clinics and peer support groups, to reduce the burden of postintensive care syndrome. We sought to discover enablers that helped hospital-based clinicians establish post-ICU clinics and peer support programs, and identify barriers that challenged them. Design: Qualitative inquiry. The Consolidated Framework for Implementation Research was used to organize and analyze data. Setting: Two learning collaboratives (ICU follow-up clinics and peer support groups), representing 21 sites, across three continents. Subjects: Clinicians from 21 sites. Measurement and Main Results: Ten enablers and nine barriers to implementation of “ICU follow-up clinics” were described. A key enabler to generate support for clinics was providing insight into the human experience of survivorship, to obtain interest from hospital administrators. Significant barriers included patient and family lack of access to clinics and clinic funding. Nine enablers and five barriers to the implementation of “peer support groups” were identified. Key enablers included developing infrastructure to support successful operationalization of this complex intervention, flexibility about when peer support should be offered, belonging to the international learning collaborative. Significant barriers related to limited attendance by patients and families due to challenges in creating awareness, and uncertainty about who might be appropriate to attend and target in advertising. Conclusions: Several enablers and barriers to implementing ICU follow-up clinics and peer support groups should be taken into account and leveraged to improve ICU recovery. Among the most important enablers are motivated clinician leaders who persist to find a path forward despite obstacles.
Molecular characterization of known and novel ACVR1 variants in phenotypes of aberrant ossification
Gupta, Aditi , Zimmermann, Michael T. , Sigafoos, Ashley N. , Macklin, Sarah , Pignolo, Robert J. , Klee, Eric W. , Macklin, Sarah K, Urrutia, Raul A, Zimmermann, Michael T , Wang, Haitao , Broski, Stephen M. , Urrutia, Raúl , Clark, Karl J. , Atwal, Paldeep S

Mayo Clinic

American Journal of Medical Genetics Part A | June 26, 2019 | Volume: 179 | Issue: 9 | Pages: 1764-1777

10.1002/ajmg.a.61274 | PMID 31240838 Get It

AbstractDiffuse idiopathic skeletal hyperostosis (DISH) is a disorder principally characterized by calcification and ossification of spinal ligaments and entheses. Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disabling disorder characterized by progressive ossification of skeletal muscle, fascia, tendons, and ligaments. These conditions manifest phenotypic overlap in the ossification of tendons and ligaments. We describe herein a patient with DISH, exhibiting heterotopic ossification of the posterior longitudinal ligament where clinical whole exome sequencing identified a variant within ACVR1, a gene implicated in FOP. This variant, p.K400E, is a novel variant, not identified previously, and occurs in a highly conserved region across orthologs. We used sequence‐based predicative algorithms, molecular modeling, and molecular dynamics simulations, to test the potential for p.K400E to alter the structure and dynamics of ACVR1. We applied the same modeling and simulation methods to established FOP variants, to identify the detailed effects that they have on the ACVR1 protein, as well as to act as positive controls against which the effects of p.K400E could be evaluated. Our in silico molecular analyses support p.K400E as altering the behavior of ACVR1. In addition, functional testing to measure the effect of this variant on BMP‐pSMAD 1/5/8 target genes was carried out which revealed this variant to cause increased ID1 and Msx2 expression compared with the wild‐type receptor. This analysis supports the potential for the variant of uncertain significance to contribute to the patient's phenotype.
Health Misinformation and the Power of Narrative Messaging in the Public Sphere
Murdoch, Blake , Brown, Jasmine M., Perrault, Sarah Tinker, Jarry, Jonathan, Anthony, Samantha J. , Ogbogu, Ubaka , Greenberg, Joshua , Zarzeczny, Amy , Hyde-Lay, Robyn, Caulfield, Timothy , Marcon, Alessandro R , Snyder, Jeremy , Brooks, Stephanie P. , Master, Zubin , Rachul, Christen M.

Mayo Clinic

Canadian Journal of Bioethics | June 18, 2019 | Volume: 2 | Issue: 2 | Pages: 52-60

10.7202/1060911ar Get It

Numerous social, economic and academic pressures can have a negative impact on representations of biomedical research. We review several of the forces playing an increasingly pernicious role in how health and science information is interpreted, shared and used, drawing discussions towards the role of narrative. In turn, we explore how aspects of narrative are used in different social contexts and communication environments, and present creative responses that may help counter the negative trends. As traditional methods of communication have in many ways failed the public, changes in approach are required, including the creative use of narratives.
PF643 CHARACTERIZATION OF FRONTLINE TREATMENT PATTERNS AND THE PROPORTION OF PATIENTS REACHING SUBSEQUENT LINES OF THERAPY IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Voorhees, Peter M. , Côté, Sarah, Lam, Annette , Ukropec, Jon, Maiese, Eric M., Nair, S. , Fonseca, Rafaël , Potluri, Ravi C. , Mehra, Mandeep R.

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 274-275

10.1097/01.hs9.0000560856.29321.96 Get It

Background:It has been well documented that each additional line of treatment is associated with lower rates of deeper responses, shorter duration of treatment, and increased rates of toxicities/comorbidities in patients with multiple myeloma (MM; Yong K, et al. Br J Haematol 2016. 175[2]:252–264). These factors contribute to treatment discontinuation and impact the proportion of patients reaching subsequent lines of therapy.Aims:To characterize the rate of therapy attrition at relapse for patients with newly diagnosed MM (NDMM) who are transplant eligible in the United States.Methods:Patients with NDMM were identified from 3 US patient‐level data sources: the OPTUM™ Commercial Claims database (period: January 2000–March 2017), the OPTUM™ Electronic Medical Records (EMR) database (period: January 2007–March 2016), and the Surveillance, Epidemiology, and End Results (SEER)‐Medicare Linked database (period: January 2007–December 2014). Patients had 1) an index MM diagnosis on or after 1 January 2007, 2) medical prescription coverage in place at diagnosis, 3) no prior malignancies in the one‐year period prior to index diagnosis, 4) a one‐year look‐back period prior to index diagnosis, and 5) received ≥1 lines of therapy. Patients were considered transplant eligible if they received stem cell transplantation anytime during the follow‐up period. Baseline characteristics including comorbidities, index age, frontline treatment regimens and attrition rates at each subsequent line of therapy were characterized. Attrition was defined as the percentage of patients who did not have any recorded subsequent MM treatments as a result of death or lost to follow‐up in the database for any reason, including end of the database.Results:A total of 1,599 patients were included in this analysis. Baseline patient characteristics and pre‐existing comorbidities are summarized in Table 1. The induction regimens used as frontline treatments included bortezomib/dexamethasone (22%), lenalidomide/dexamethasone (13%), bortezomib/lenalidomide/dexamethasone (25%), all other bortezomib combinations (20%), and other (20%). The proportions of patients observed to progress to each subsequent line of therapy are summarized in Table 2. In total, 77% of patients received a second line of therapy, and only 55% received a third line treatment. The proportion of patients not receiving a subsequent line of therapy due to death is also summarized by lines of therapy in Table 2.Summary/Conclusion:A substantial number of patients with NDMM who are transplant eligible did not receive subsequent lines of therapy, with attrition by lines of therapy ranging from 23–40%. The increase in attrition rates with each additional line of therapy underscores the need to utilize upfront therapy associated with optimal progression‐free survival. Further studies evaluating the etiologic basis for this unexpectedly high attrition rate are warranted.image
SaO005CLINICAL PRESENTATION AND PROGNOSIS OF DNAJB11-ASSOCIATED NEPHROPATHY: AN INTERNATIONAL COLLABORATIVE STUDY
Huynh, Vinh Toan, Audrézet, Marie‐Pierre , Domenger, C. , Longuet, Hélène, Halimi, Jean‐Michel , Genkyst, Study Group, Pajot, Aurélie, Albaret, Julie, Ponlot, Eléonore , Ong, Albert , Ong, Albert C M , Bridoux, Frank , Séret, Guillaume , Senum, Sarah R. , Férec, Claude , Eerde, Albertien M. van , Harris, Peter C. , Meur, Yannick Le , Gall, Émilie Cornec-Le

Mayo Clinic

Nephrology Dialysis Transplantation | June 13, 2019 | Volume: 34 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfz101.sao005 Get It

Does Donor Allograft Microsteatosis Matter? Comparison of Outcomes in Liver Transplantation With a Propensity‐Matched Cohort
Croome, Kristopher P. , Lee, David D. , Croome, Sarah, Nakhleh, Raouf E. , Senada, Peter A., Yataco, Maria, Abader Sedki Senada, Peter, Livingston, David, Taner, C. Burcin , Croome, Kris P , Lee, David D , Livingston, David H.

Mayo Clinic

Liver Transplantation | June 12, 2019 | Volume: 25 | Issue: 10 | Pages: 1533-1540

10.1002/lt.25583 | PMID 31187923 Get It

It has been suggested that microsteatosis does not negatively impact graft survival following liver transplantation (LT). The present study represents the largest series on donor livers with significant microsteatosis and investigates the impact of microsteatosis on perioperative factors such as postreperfusion syndrome (PRS), early allograft dysfunction (EAD), and postoperative renal dysfunction. Clinical outcomes of all patients undergoing LT with donor livers with isolated microsteatosis (≥30%; n = 239) between 2000 and 2017 were compared with a propensity score–matched cohort of patients undergoing LT with donor livers with no steatosis (n = 239). Patients in the microsteatosis group had a higher rate of PRS (33.1% versus 24.2%; P = 0.03), EAD (38.2% versus 23.0%; P < 0.001), and continuous renal replacement therapy (CRRT) requirement following LT (10.9% versus 3.6%; P = 0.002) than the no steatosis group. No difference in patient (P = 0.33) or graft survival (P = 0.18) was observed between the 2 groups. On multivariate regression, livers with microsteatosis had an increased risk of graft loss with retransplant recipients (hazard ratio [HR], 1.59; P < 0.001), increasing Model for End‐Stage Liver Disease (MELD) score (HR, 1.13; P = 0.01), and organs from donation after circulatory death donors (HR, 1.46; P = 0.003). In conclusion, recipients of donor livers with significant microsteatosis are at an increased risk of PRS, EAD, and postoperative renal dysfunction requiring CRRT. Livers with significant microsteatosis should be avoided in retransplant recipients and in recipients with high biological MELD scores. Once appropriately selected recipients of these livers are able to overcome the initial perioperative implications of using these donor livers, longterm patient and graft survival is similar to recipients receiving grafts with no steatosis.